Peptide properties

1Top 2Function-activity relationship 3Calculated physicochemical properties 4Peptide source & Food-borne protein(s) search 5Biological/Functional activity & target protein 6Taste properties & Structure 7Preparation method 8Stability & Cytotoxicity 9Additional information 10Database cross-references 11Reference(s)

List of peptide properties

DFBP ID - DFBPANCA0334(Anticancer peptide)

DFBP ID	DFBPANCA0334
Peptide sequence	FKCRRWQWRMKKLGAPSITCVRRAF
Type	Native peptide
Peptide/Function name	Anticancer peptide, LfcinB

Function-activity relationship

Main bioactivity	Anticancer activity
Otheir bioactivity	Antimicrobial activity ^[D1], Immunomodulatory activity ^[D2], Multifunctional activity ^[D3]

Calculated physicochemical properties

Three-letter amino acid

Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-Pro-Ser-Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe

Single-letter amino acid

FKCRRWQWRMKKLGAPSITCVRRAF

Peptide length

Peptide mass

Experimental mass	Theoretical mass
N.D	3125.80 Da ^c

Net charge

0.00 ^c

Isoelectric point (pI)

12.34 ^c

IC₅₀

N.D

pIC₅₀

N.D

GRAVY

-0.5760^c

Hydrophilic residue ratio

48%^c

Peptide calculator

Peptide source & Food-borne protein(s) search

Classification	Animal
Organism/Source	Bovine milk protein
Precursor protein	Lactoferricin
Residue position	N.D
Precursor protein(s) search	Source.1: DFBPPR8500 ---- Milk proteins ---- Lactotransferrin
Link-research Inductive analysis	Link 1: DFBPANCA0007----Bovine milk----Lactoferricin (LfcinB) peptide from bovine lactoferrin Link 2: DFBPANCA0055----Bovine milk----Lactoferrin (LF-B)

Biological/Functional activity & target protein

Anticancer activity

Angiogenesis is a complex process whereby new blood vessels form from pre-existing vasculature in response to proangiogenic factors such as basic fibroblast growth factor (bFGF) and the 165-kd isoform of vascular endothelial growth factor (VEGF₁₆₅). Angiogenesis inhibitors show considerable potential in the treatment of cancer because angiogenesis is necessary for tumor growth beyond a few millimeters in diameter because of the tumor’s need for oxygen and nutrient supply, as well as waste removal.
In vivo and in vitro evidence demonstrate that LfcinB has potent antiangiogenic activity. LfcinB strongly inhibited both bFGF- and VEGF₁₆₅-induced angiogenesis in Matrigel plugs implanted in C57BL/6 mice. In addition, LfcinB inhibited the in vitro proliferation and migration of human umbilical vein endothelial cells (HUVECs) in response to bFGF or VEGF165 but was not cytotoxic to HUVECs. Rather , LfcinB complexed with heparin-like structures on the HUVEC surface that are involved in the binding of bFGF and VEGF165 to their respective receptors, thereby preventing receptor-stimulated angiogenesis.

Specific target protein(s)

N.D

Taste properties & Structure

Bitterness

Literature report	N.D
Bitter prediction tools	Bitter taste ^prediction

SMILES

N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O

Preparation method

Mode of preparation	Synthetic peptide
Enzyme(s)/starter culture	LfcinB (amino acid sequence: FKCRRWQWRMKKLGAPSITCVRRAF) and biotinylated LfcinB were synthesized in linear form by Sigma Genosys (The Woodlands, TX) with a purity of greater than 95%.

Stability & Cytotoxicity

Peptide stability

Literature report:	N.D
EHP-Tool:	Enzymatic Hydrolysis Prediction Tool (EHP-Tool)

Peptide cytotoxicity

Literature report:	N.D
Prediction:	ToxinPred

Additional information

LfcinB may have utility as an antiangiogenic agent for the treatment of human cancers.

Database cross-references

DFBP

[D1]	DFBPAMIC0005
[D2]	DFBPIMMU0026
[D3]	DFBPMUFU0698

BIOPEP-UWM

[D4]

3229, 7051, 8175

APD

[D5]

BioPepDB

[D6]

MBPDB

[D7]

Reference(s)

Primary literature	Mader JS, Smyth D, Marshall J, Hoskin DW. Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am J Pathol. 2006 Nov;169(5):1753-66. PMID: 17071598 DOI: 10.2353/ajpath.2006.051229
Other literature(s)	[1] Udenigwe C C , Hannah W , Gong M , et al. Preclinical Evidence on the Anticancer Properties of Food Peptides[J]. Protein Pept Lett, 2017, 24(2):-.
PubDate	2006